Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease.

Human vaccines & immunotherapeutics - 3 Jun 2017

Hegde Nagendra R, Gore Milind M

Abstract excerpt

Japanese encephalitis (JE) is a serious public health concern in most of Asia. The disease is caused by JE virus (JEV), a flavivirus transmitted by Culex mosquitoes. Several vaccines have been developed to control JE in endemic areas as well as to protect travelers and military personnel who visit or are commissioned from non-endemic to endemic areas. The vaccines include inactivated vaccines produced in mouse...

Topics

Join the communities discussing this publication.

Asia
Cross Protection
Cross Reactions
Encephalitis, Japanese
Encephalitis Virus, Japanese

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Vaccines, Attenuated

Vaccines, Inactivated

Vaccines, Synthetic

Source

Open in PubMed Open full text

Identifiers

PMID: 28301270
DOI: 10.1080/21645515.2017.1285472
PMCID: PMC5529032

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease.PMID 28301270Read ↗

Safety and Immunogenicity of a Single Administration of Live-attenuated Japanese Encephalitis Vaccine in Previously Primed 2- to 5-year-olds and Naive 12- to 24-month-oldsSemantic proximity Read ↗

Japanese encephalitis and Japanese encephalitis virus in mainland China.Semantic proximity Read ↗

The hidden threats posed by Japanese encephalitis virus genotype V.Semantic proximity Read ↗

Safety and immunogenicity of a live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) in childrenSemantic proximity Read ↗

Development of New Vaccines against Dengue Fever and Japanese EncephalitisSemantic proximity Read ↗

Shift in dominant genotypes of Japanese encephalitis virus and its impact on current vaccination strategiesSemantic proximity Read ↗

Study on the Protective Efficacy of the Japanese Encephalitis Live Attenuated Vaccine SA14-14-2 Against Newly Isolated Genotype I Japanese Encephalitis Viruses.Semantic proximity Read ↗

From the World Health Organization. Development of dengue and Japanese encephalitis vaccines.Semantic proximity Read ↗

A Chimeric Dengue Virus Vaccine using Japanese Encephalitis Virus Vaccine Strain SA14-14-2 as Backbone Is Immunogenic and Protective against Either Parental Virus in Mice and Nonhuman PrimatesSemantic proximity Read ↗

Comparison of Neutralizing Antibody Titers against Japanese Encephalitis Virus Genotype V Strain with Those against Genotype I and III Strains in the Sera of Japanese Encephalitis Patients in Japan in 2016.Semantic proximity Read ↗

Low Protective Efficacy of the Current Japanese Encephalitis Vaccine against the Emerging Genotype 5 Japanese Encephalitis Virus.Semantic proximity Read ↗

Mouse and Human Monoclonal Antibodies Protect against Infection by Multiple Genotypes of Japanese Encephalitis Virus.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.